Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on Informa

(Sharecast News) - Analysts at Berenberg lowered their target price on publishing and exhibitions group Informa from 1,070.0p to 930.0p per share on Tuesday but said the group was still "standing strong". Berenberg said Informa's share price has "suffered" recently on investors' concerns about the potential effects of an economic downturn and US funding cuts to academia.

The German bank noted the "cyclicality and structural growth potential" of Informa's B2B events division, and assessed the impact that potential cuts to US government university funding could have on its Taylor and Francis subsidiary.

"We conclude that the B2B events sector is less cyclical than investors think, and that the impact on T&F should be limited," said Berenberg, which reiterated its 'buy' rating on the stock despite dropping its target price on the shares.

With the shares trading on a CY25 price-to-earnings ratio of 14.6x, for a 10% earnings per share compound annual growth rate over FY24-28 when including buybacks, Berenberg views Informa's current valuation as "an attractive buying opportunity".

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.